Evidence map›Paper›PMID 36471498›Full record

ReviewPediatrics2023

Mpox in Children and Adolescents: Epidemiology, Clinical Features, Diagnosis, and Management.

Amy M Beeson, Julia Haston, David W McCormick, Mary Reynolds, Kevin Chatham-Stephens, Andrea M McCollum, Shana Godfred-Cato

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06844487 (Phase 3, Randomised Maternal and Infant), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06844487 phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

TypeinterventionalSponsorJean-Pierre Van geertruydenRan2025 to 2027Enrolled344ConditionsMpox (Monkeypox), Vaccination, Immunogenicity, SafetyArmsMVA-BN standard regimen, MVA-BN half-dose regimen
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Mpox and oral health among children in Africa.Frontiers in oral health · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amy M BeesonCenters for Disease Control and Prevention, Atlanta, Georgia.
Julia HastonCenters for Disease Control and Prevention, Atlanta, Georgia.
David W McCormickCenters for Disease Control and Prevention, Atlanta, Georgia.
Mary ReynoldsCenters for Disease Control and Prevention, Atlanta, Georgia.
Kevin Chatham-StephensCenters for Disease Control and Prevention, Atlanta, Georgia.
Andrea M McCollumCenters for Disease Control and Prevention, Atlanta, Georgia.
Shana Godfred-CatoCenters for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · USEpidemic Intelligence Service · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Although mpox is rare among children in the United States, pediatric cases are being reported during the 2022 multinational mpox outbreak. Vaccines and antiviral medications developed for other orthopoxviruses have recently become widely used to prevent and treat mpox in both children and adults in the United States. Although scientific literature regarding mpox in children and adolescents is scant, prior case reports can provide valuable information about the clinical features and potential complications of untreated clade II mpox in these age groups. In this review, we summarize the epidemiology and clinical features of mpox in children and adolescents and provide recommendations for clinicians regarding its diagnosis, management, and prevention. Robust, dedicated surveillance of pediatric exposures and cases in the current outbreak, including the use of vaccines and therapeutics, are needed to guide clinical management and public health strategies.

Indexed as

Mpox, MonkeypoxAdolescentAntiviral AgentsChildHumansPopulation SurveillancePublic HealthUnited StatesAntiviral Agents

Identifiers

PMID36471498
PMCPMC9995221
OpenAlexW4310783829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.